Full Press Release Details
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi.
KYMR
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
Key Takeaway: Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
Price reaction · baseline $22.09 (2023-12-06 close) · hit after-hours · 1 other KYMR headline(s) in the window, move may be shared
day 0 close · peak
+7.2%
day 1
+4.1%
day 3
+2.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
4.3%
average across 7 past catalysts
Cash runway
~83 mo
Minimal dilution risk
Lead asset
KT-621
Phase 2 · Atopic Dermatitis